MedTrace Logo

Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fed Conditions

NCT01380496 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-09-26

No results posted yet for this study

Summary

The purpose of this study is to compare the single-dose bioequivalence of Par and Oclassen doxycycline monohydrate 100 mg.

Conditions

  • To Determine Bioequivalence Under Fed Conditions

Interventions

DRUG

doxycycline monohydrate

tablet, 100 mg, single, oral dose

DRUG

doxycycline monohydrate

Capsule, 100 mg, single, oral dose

DRUG

doxycycline monohydrate

Capsule, 100 mg, single, oral dose

Sponsors & Collaborators

  • Anapharm

    collaborator INDUSTRY

  • Par Pharmaceutical, Inc.

    lead INDUSTRY

Principal Investigators

  • Eric Masson, Pharm D. · Anapharm

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1999-11-30
Primary Completion
1999-11-30
Completion
1999-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01380496 on ClinicalTrials.gov